Rumba Mens Health Blog

Men’s Health News
A new study by researchers in Finland has some advice for older men when it comes to preserving their sexual function.
The new advice basically says, "use or lose it", the more sex older men have the lower their risk of developing erectile dysfunction (ED).
The researchers advise men who want to preserve their sexual function to have sex often.
generic cipro online buy The researchers conducted a study that tracked 989 older Finnish men between the ages of 55 and 75 for a five year period and found those who were regularly having sex at the start of the study were at lower risk of developing ED by the end of the study.
The average age of the men was 59 years old, most were married or cohabitating, more than half of them were overweight and nearly half had at least one chronic medical condition.
The researchers say the more often the men had sex, the lower their ED risk which suggests that men should be encouraged to stay sexually active as they age.
Dr. Juha Koskimaki and colleagues at the University of Tampere in Finland say those who said they had sex less than once per week were twice as likely to develop ED over the next five years as men who had sex at least once a week.
Compared with men who had sex three or more times per week, their ED risk was increased almost four times.
Erectile dysfunction is caused by a number of contributing factors such as age, diabetes and heart disease….many of which could also affect a man’s sexually activity.
The researchers found however, even after these factors were allowed for, sexual activity itself remained linked to ED risk, and they say it may well be a case of "use it or lose it".
According to the researchers just as exercise boosts physical fitness, regular sexual activity may help a man preserve his erectile function by helping to maintain healthy blood vessel function in the erectile tissue.
Koskimaki and colleagues did not ask the men about masturbation, which they say might also have the same effect on erectile dysfunction as intercourse.
The study is published in the American Journal of Medicine, July 2008.
Generic acomplia pills no prescription | Buy lasix without prescription | Buy generic soma

More people suffer from being overweight and have high blood pressure and metabolic disturbances in East Germany than in West Germany. This is the result of a study with almost 36 000 patients, published in the current edition of the Deutsches ?

Men’s Health News
Is screening or treatment for prostate cancer the reason for decreased mortality in the USA, compared to the UK?
The striking decline in prostate cancer mortality in the USA, compared with the UK in 1994-2004, coincided with a much higher uptake of screening in the USA.
Nevertheless, conclude researchers at the University of Bristol, speculation over the role of screening and treatment for prostate cancer will continue until evidence from randomised controlled trials is published. generic viagra online buy Their study and conclusions are published online (17 April) in The Lancet Oncology.
In the USA, prostate cancer screening based on the prostate-specific antigen (PSA) test, is almost routine. In 2001, 57% of men aged 50 years or older reported having a PSA test within the previous 12 months. By contrast, for each year between 1999 and 2002, an estimated 6% of men aged 45-84 were tested in the UK.
However, there is no robust evidence that routine PSA testing decreases prostate cancer mortality. Previously published comparisons of USA/UK prostate cancer trends - using data up to the late 1990s - showed that mortality rates in the USA and UK had begun to fall, albeit more rapidly in the USA, but the changes seemed too early to be attributed to the effect of PSA testing.
Simon Collin, from the University of Bristol, UK, and colleagues analysed trends in prostate cancer mortality in both countries between 1975 and 2004, and compared them with trends in screening and treatment.
They found that mortality rates peaked in the early 1990s and then began to decline, but after 1994, the rate of decline of mortality in the USA (4.17% per year) was almost four times that in the UK (1.17% per year). The mortality decline in the USA was greatest and most sustained in patients aged 75 years or older, whereas death rates stabilised in this age group in the UK by 2000.
The authors say that the difference in mortality could be related to different treatment and screening policies in the two countries - for example the greater use of gonadotropin-releasing hormone treatment in older men, or more aggressive treatment of men with locally advanced and asymptomatic prostate cancer found through greater PSA testing in the USA. Another factor could be the misattribution of cause of death.
They conclude: "The decline in mortality from prostate cancer in the USA is striking in comparison to the UK, but we can only continue to speculate about the relative contributions of differences in detection and treatment, or the relative balance of benefits and harms, until the publication of findings from trials provides the robust evidence that is so eagerly awaited."
In addition, the findings from this paper give support to the views from the British Association of Urological Surgeons that many recommendations in recently released UK NICE Guidance are unfounded, inappropriate and risk worsening mortality rates in the UK from prostate cancer.
Please contact Cherry Lewis for further information.
Further information:
The paper: Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study by Simon M Collin, Richard M Martin, Chris Metcalfe, David Gunnell, Peter Albertsen, David Neal, Freddie Hamdy, Peter Stephens, J Athene Lane, Rollo Moore and Jenny Donovan. Lancet Oncology, 2008; 9: 445-52.

Buy generic cipro | generic propecia online buy | Generic soma pills no prescription

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration has granted tentative approval for the Company’s Abbreviated New Drug Application (ANDA) to market its generic version of Novartis’ hypertension treatment Diovan® (Valsartan) Tablets, 40 mg, 80 mg, 160 mg and 320 mg. Final approval of this product is expected upon expiry of patent protection for the brand product in September 2012, as well as any periods of marketing exclusivity that may be awarded.
The brand product had U.S. sales of approximately $1.5 billion for the twelve months ended March 30, 2008, according to IMS data.
About Teva
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world’s leading generic pharmaceutical company. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Teva’s sales are in North America and Europe.
generishe cialis pillen Ohne Rezept Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management’s current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: Teva’s ability to accurately predict future market conditions, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra®, Neurontin®, Lotrel®, Famvir® and Protonix®, Teva’s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may prevent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, the effects of competition on our innovative products, especially Copaxone® sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva’s ability to successfully identify, consummate and integrate acquisitions (including the pending acquisition of Bentley Pharmaceuticals, Inc.), potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Teva’s Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Teva Pharmaceutical Industries Ltd.
View drug information on Allegra; Copaxone; Diovan.
generishe cialis pillen Ohne Rezept | Kaufen generishe viagra soft | generishe viagra online kaufen mastercard

Biovail Corporation (NYSE: BVF) (TSX: BVF) announced that it has received Approval from the United States Food and Drug Administration (FDA) for its New Drug Application (NDA) for Aplenzin™ (formerly known as BVF-033), a once-daily formulation of bupropion hydrobromide developed by Biovail for the treatment of depression in adults.
Aplenzin™ is an alcohol-resistant formulation of a new bupropion salt and has been approved in 174mg, 348mg, and 522mg extended-release tablets. The 522mg dosage strength provides patients requiring the maximum allowable dose of bupropion the only single tablet, once-daily option.
Biovail remains in active partnership discussions for the commercialization rights for Aplenzin™ in the United States.
About Biovail Corporation
comprare levitra mastercard Biovail Corporation is a specialty pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products utilizing advanced drug-delivery technologies.
Biovail Corporation
generico viagra soft in linea comrare | comprare il cialis soft senza ricetta | comprare il levitra senza ricetta